← 返回前沿论文

OGN 在泛癌中的临床效用:诊断生物标志物和免疫微环境调节因子

英文原题:Clinical utility of OGN in pan-cancer: diagnostic biomarker and immune microenvironment regulator.

PubMed 2026/01/27(内容时间) Transl Cancer Res Q3 · IF 2.1(JCR 2025)

研究概要

我们的泛癌分析强调OGN是一种依赖于背景的调节因子,将细胞外基质(ECM)重塑与免疫和血管生成信号联系起来。其在泛癌中的失调、诊断/预后价值以及与免疫逃逸机制的串扰,表明OGN是一种有前景的多功能生物标志物和治疗靶点。

研究思路结论见上方概要

骨甘氨酸(OGN)是一种细胞外基质蛋白,其在癌症中的作用逐渐受到关注,但特征尚不明确。本研究首次对OGN的表达模式、临床意义、免疫相互作用及功能机制进行了泛癌种研究。

来自Genotype Tissue Expression (GTEx)、Cancer Cell Line Encyclopedia (CCLE)、The Cancer Genome Atlas (TCGA)和Human Protein Atlas (HPA)数据库的多组学数据被整合。在正常组织和肿瘤样本中分析差异表达。使用受试者工作特征(ROC)曲线的曲线下面积(AUC)评估诊断效用。通过Kaplan-Meier[总生存期(OS);疾病特异性生存期(DSS);无病间期(DFI);无进展间期(PFI)]和Cox回归分析评估预后价值。使用ESTIMATE、CIBERSORT和基因集富集量化免疫微环境相关性。通过基因集富集分析(GSEA)以及与标志性癌症特征的相关性探索功能通路。

OGN在正常组织(脑、肝、肾)中广泛表达,但在大多数肿瘤类型中显著下调(P<0.05,TCGA;在蛋白质水平验证,HPA)。OGN在泛癌中表现出高诊断准确性(AUC:0.703-0.990),在结肠腺癌(COAD)(AUC:0.966)和甲状腺癌(THCA)(AUC:0.920)中达到近乎完美的性能。OGN高表达与胸腺瘤(THYM)(OS/DSS)和胆管癌(CHOL)(PFI/DFI)的改善生存结局相关,但在肺腺癌/肝细胞癌(LUAD/LIHC)中预后更差,表明癌症类型特异性。OGN表达与免疫细胞浸润(巨噬细胞、NK 细胞、T细胞)、趋化因子信号、程序性死亡配体1(PD-L1)水平、微卫星不稳定性(MSI)和肿瘤突变负荷(TMB)强烈相关。GSEA揭示OGN相关基因在跨癌症的上皮-间质转化(EMT)、血管生成、JAK-STAT和PI3K通路中富集。

展开英文摘要原文

BACKGROUND: Osteoglycin (OGN), an extracellular matrix protein, has emerging but poorly characterized roles in cancer. This study presents the first pan-cancer investigation of OGN's expression patterns, clinical significance, immune interactions, and functional mechanisms. METHODS: Multi-omics data from Genotype Tissue Expression (GTEx), Cancer Cell Line Encyclopedia (CCLE), The Cancer Genome Atlas (TCGA), and Human Protein Atlas (HPA) databases were integrated. Differential expression was analyzed in normal tissues and tumor samples. Diagnostic utility was evaluated using area under the curve (AUC) of receiver operating characteristic (ROC) curve. Prognostic value was assessed via Kaplan-Meier [overall survival (OS); disease-specific survival (DSS); disease free interval (DFI); progression-free interval (PFI)] and Cox regression analyses. Immune microenvironment correlations were quantified using ESTIMATE, CIBERSORT, and gene set enrichment. Functional pathways were explored through gene set enrichment analysis (GSEA) and correlation with hallmark cancer signatures. RESULTS: OGN was broadly expressed in normal tissues (brain, liver, kidney) but significantly downregulated in most tumor types (P<0.05, TCGA; validated at protein level, HPA). OGN demonstrated high diagnostic accuracy in pan-cancer (AUC: 0.703-0.990), achieving near-perfect performance in colon adenocarcinoma (COAD) (AUC: 0.966) and thyroid cancer (THCA) (AUC: 0.920). High OGN expression correlated with improved survival outcomes in thymoma (THYM) (OS/DSS) and cholangiocarcinoma (CHOL) (PFI/DFI), but worse prognosis in lung adenocarcinoma​/liver hepatocellular carcinoma​ (LUAD/LIHC), indicating cancer-type specificity. OGN expression strongly associated with immune cell infiltration (macrophages, natural killer cells, T cells), chemokine signaling, programmed death-ligand 1 (PD-L1) levels, microsatellite instability (MSI), and tumor mutation burden (TMB). GSEA revealed enrichment of OGN-linked genes in epithelial-mesenchymal transition (EMT), angiogenesis, JAK-STAT, and PI3K pathways across cancers. CONCLUSIONS: Our pan-cancer analysis highlights OGN as a context-dependent regulator linking extracellular matrix (ECM) remodeling with immune and angiogenic signaling. Its pan-cancer dysregulation, diagnostic/prognostic value, and crosstalk with immune evasion mechanisms nominate OGN as a promising multi-functional biomarker and therapeutic target.

论文信息

作者
Chen X、Wang X、Peng J
第一作者单位
Department of Cancer Medical Center, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.China
通讯作者单位
Anhui Institute of Pediatric Research, Anhui Provincial Children's Hospital, Hefei, China.China
期刊
Translational cancer research2026 Jan 31
原文标识
PubMed 41674945 · DOI 10.21037/tcr-2025-1499